BIOMAT Database Logo BIOMAT Database Logo

[A study on therapeutic effects of enviomycin in retreatment for drug resistant pulmonary tuberculosis (author's transl)]. 1979

K Kondo, and A Kuze, and S Sato, and S Kurematu, and S Tateno, and T Shimizu, and J Arima, and K I Yamamoto, and H Obara, and H Hiraga, and N Takada, and Y Kon, and H Takagi, and H Kakinoki, and M Mituka, and S Ueda, and K Takayama, and N Ueda, and T Kuwajima, and Y Sakai, and E Hamano, and K Aikawa, and S Hasegawa, and M Abe, and M Tanaka, and Y Yokoyama, and A Suzuki

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D004776 Enviomycin Cyclic basic peptide related to VIOMYCIN. It is isolated from an induced mutant of Streptomyces griseoverticillatus var. tuberacticus and acts as an antitubercular agent with less ototoxicity than tuberactinomycin. Tuberactinomycin N,Tuberactinomycin-N
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000904 Antibiotics, Antitubercular Substances obtained from various species of microorganisms that are, alone or in combination with other agents, of use in treating various forms of tuberculosis; most of these agents are merely bacteriostatic, induce resistance in the organisms, and may be toxic. Antitubercular Antibiotics
D014397 Tuberculosis, Pulmonary MYCOBACTERIUM infections of the lung. Pulmonary Consumption,Pulmonary Phthisis,Pulmonary Tuberculoses,Pulmonary Tuberculosis,Tuberculoses, Pulmonary,Consumption, Pulmonary,Consumptions, Pulmonary,Phthises, Pulmonary,Phthisis, Pulmonary,Pulmonary Consumptions,Pulmonary Phthises

Related Publications

K Kondo, and A Kuze, and S Sato, and S Kurematu, and S Tateno, and T Shimizu, and J Arima, and K I Yamamoto, and H Obara, and H Hiraga, and N Takada, and Y Kon, and H Takagi, and H Kakinoki, and M Mituka, and S Ueda, and K Takayama, and N Ueda, and T Kuwajima, and Y Sakai, and E Hamano, and K Aikawa, and S Hasegawa, and M Abe, and M Tanaka, and Y Yokoyama, and A Suzuki
[A study on therapeutic effect of enviomycin (tuberactin) in retreatment for pulmonary tuberculosis (author's transl)].
February 1978, Kekkaku : [Tuberculosis],
K Kondo, and A Kuze, and S Sato, and S Kurematu, and S Tateno, and T Shimizu, and J Arima, and K I Yamamoto, and H Obara, and H Hiraga, and N Takada, and Y Kon, and H Takagi, and H Kakinoki, and M Mituka, and S Ueda, and K Takayama, and N Ueda, and T Kuwajima, and Y Sakai, and E Hamano, and K Aikawa, and S Hasegawa, and M Abe, and M Tanaka, and Y Yokoyama, and A Suzuki
[Clinical study of enviomycin (EVM) in pulmonary tuberculosis (author's transl)].
April 1978, Kekkaku : [Tuberculosis],
K Kondo, and A Kuze, and S Sato, and S Kurematu, and S Tateno, and T Shimizu, and J Arima, and K I Yamamoto, and H Obara, and H Hiraga, and N Takada, and Y Kon, and H Takagi, and H Kakinoki, and M Mituka, and S Ueda, and K Takayama, and N Ueda, and T Kuwajima, and Y Sakai, and E Hamano, and K Aikawa, and S Hasegawa, and M Abe, and M Tanaka, and Y Yokoyama, and A Suzuki
[Studies on the therapeutic effects of lividomycin in retreatment for pulmonary tuberculosis (author's transl)].
January 1974, Kekkaku : [Tuberculosis],
K Kondo, and A Kuze, and S Sato, and S Kurematu, and S Tateno, and T Shimizu, and J Arima, and K I Yamamoto, and H Obara, and H Hiraga, and N Takada, and Y Kon, and H Takagi, and H Kakinoki, and M Mituka, and S Ueda, and K Takayama, and N Ueda, and T Kuwajima, and Y Sakai, and E Hamano, and K Aikawa, and S Hasegawa, and M Abe, and M Tanaka, and Y Yokoyama, and A Suzuki
[Adverse reactions of enviomycin during treatment for pulmonary tuberculosis (author's transl)].
April 1980, Kekkaku : [Tuberculosis],
K Kondo, and A Kuze, and S Sato, and S Kurematu, and S Tateno, and T Shimizu, and J Arima, and K I Yamamoto, and H Obara, and H Hiraga, and N Takada, and Y Kon, and H Takagi, and H Kakinoki, and M Mituka, and S Ueda, and K Takayama, and N Ueda, and T Kuwajima, and Y Sakai, and E Hamano, and K Aikawa, and S Hasegawa, and M Abe, and M Tanaka, and Y Yokoyama, and A Suzuki
[Tuberactinomycin-N (enviomycin-EVM) in the treatment of pulmonary tuberculosis (author's transl)].
July 1981, Kekkaku : [Tuberculosis],
K Kondo, and A Kuze, and S Sato, and S Kurematu, and S Tateno, and T Shimizu, and J Arima, and K I Yamamoto, and H Obara, and H Hiraga, and N Takada, and Y Kon, and H Takagi, and H Kakinoki, and M Mituka, and S Ueda, and K Takayama, and N Ueda, and T Kuwajima, and Y Sakai, and E Hamano, and K Aikawa, and S Hasegawa, and M Abe, and M Tanaka, and Y Yokoyama, and A Suzuki
[A clinical study of enviomycin (EVM) for pulmonary tuberculosis and a case report of lung autopsy treated originally with EVM (author's transl)].
May 1978, Kekkaku : [Tuberculosis],
K Kondo, and A Kuze, and S Sato, and S Kurematu, and S Tateno, and T Shimizu, and J Arima, and K I Yamamoto, and H Obara, and H Hiraga, and N Takada, and Y Kon, and H Takagi, and H Kakinoki, and M Mituka, and S Ueda, and K Takayama, and N Ueda, and T Kuwajima, and Y Sakai, and E Hamano, and K Aikawa, and S Hasegawa, and M Abe, and M Tanaka, and Y Yokoyama, and A Suzuki
[Therapeutic effects of lividomycin in the retreatment for pulmonary tuberculosis patients].
April 1973, Kekkaku : [Tuberculosis],
K Kondo, and A Kuze, and S Sato, and S Kurematu, and S Tateno, and T Shimizu, and J Arima, and K I Yamamoto, and H Obara, and H Hiraga, and N Takada, and Y Kon, and H Takagi, and H Kakinoki, and M Mituka, and S Ueda, and K Takayama, and N Ueda, and T Kuwajima, and Y Sakai, and E Hamano, and K Aikawa, and S Hasegawa, and M Abe, and M Tanaka, and Y Yokoyama, and A Suzuki
[Clinical study on tuberactinomycin-N (TUM-N) and viomycin (VM) in retreatment of pulmonary tuberculosis (author's transl)].
July 1974, Kekkaku : [Tuberculosis],
K Kondo, and A Kuze, and S Sato, and S Kurematu, and S Tateno, and T Shimizu, and J Arima, and K I Yamamoto, and H Obara, and H Hiraga, and N Takada, and Y Kon, and H Takagi, and H Kakinoki, and M Mituka, and S Ueda, and K Takayama, and N Ueda, and T Kuwajima, and Y Sakai, and E Hamano, and K Aikawa, and S Hasegawa, and M Abe, and M Tanaka, and Y Yokoyama, and A Suzuki
[A study on pulmonary tuberculosis retreatment cases].
December 2003, Kekkaku : [Tuberculosis],
K Kondo, and A Kuze, and S Sato, and S Kurematu, and S Tateno, and T Shimizu, and J Arima, and K I Yamamoto, and H Obara, and H Hiraga, and N Takada, and Y Kon, and H Takagi, and H Kakinoki, and M Mituka, and S Ueda, and K Takayama, and N Ueda, and T Kuwajima, and Y Sakai, and E Hamano, and K Aikawa, and S Hasegawa, and M Abe, and M Tanaka, and Y Yokoyama, and A Suzuki
Multiple retreatment drug regimens for pulmonary tuberculosis.
April 1966, Annals of the New York Academy of Sciences,
Copied contents to your clipboard!